Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) announced the pricing of its underwritten public offering in connection with its uplisting to the Nasdaq Capital Market. The offering consists of 2.4 million common shares at US$6.25 per share, with expected gross proceeds of approximately US$15 million, excluding any exercise of the underwriter's option to purchase up to an additional 360,000 shares. Joseph Gunnar & Co. LLC is acting as sole book-running manager for the offering, with trading on Nasdaq expected to begin May 20, 2026, under the symbol OPTH.
The company stated it intends to use the net proceeds to scale production and distribution of its psychedelic drug products, support market expansion including into the United States, and fund sales growth, working capital, and operating expenses. Optimi also confirmed the effectiveness of its previously announced 1-for-30 share consolidation, resulting in approximately 3.2 million common shares outstanding prior to the offering, subject to rounding and any additional issuances.
Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. The company supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country's Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.
This uplisting to Nasdaq marks a significant milestone for Optimi, potentially increasing its visibility and access to a broader investor base. The capital raised is expected to accelerate its production capabilities and market expansion, particularly in the United States, where psychedelic-assisted therapies are gaining regulatory attention. The offering could also impact the broader psychedelic pharmaceutical industry by signaling investor confidence in the sector's growth prospects.
For more information, visit the full press release at https://ibn.fm/iwNJ5 and the company's website at https://www.optimi.net/.
